On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


The Movie Studio Inc. (MVES) Disruptive VOD Technology Gaining Ground Via Advertising Agreement with eStreamTV

  • MVES signs agreement with eStreamTV to integrate advertising into its VOD application
  • Full launch of app expected in fall 2020, campaigns to follow on Instagram and Facebook
  • Revenue strategy includes both paid membership and “free” content with advertising

As consumer preferences continue to gravitate towards Video on Demand (“VOD”), The Movie Studio (OTC: MVES), a vertically integrated motion picture production and distribution company, continues to make headway in the industry by integrating its unique revenue model with a new advertising channel agreement with eStreamTV, a provider of integrated programmatic advertising on television platforms. By combining both advertisement-based and recurring revenue models, MVES’s disruptive technology enables it to break the boundaries set by the industry, allowing the company to gain new ground lost by legacy motion picture pathways.

Based on a revenue-sharing model that features the integration of eStreamTV into MVES’s new app, the partnership between the two companies will initially focus on the insertion of advertising into the app’s advertiser video on demand (“AVOD”) component. Currently “soft” launched in the Google Play Store and the Apple App Store, the full launch of the app is expected to take place in early fall 2020 with a full integration of eStreamTV, followed by a targeted campaign on Instagram and Facebook that will focus primarily on millennials along with other key demographic audiences.

“We are extremely excited about AVOD integration into the upcoming launch of our app and OTT platform,” said MVES president and CEO Gordon Scott Venters (http://ibn.fm/CzJmn). “Upon completion, this could create a significant user subscription base as a ‘free’ movie ingestion platform and a unique brand and disruptor entering the exciting VOD space in the app OTT and smart TV universe.”

Powered by multiple advertising partners that deliver programmatic video ads, eStreamTV’s advertiser service provides professional broadcast-style ad breaks that can be adjusted to the individual content platform’s preference. Ads served to viewers are suited to their tastes and consumer preferences through the integration of programmatic ad tags that offer higher monetization potential. Through the use of a split-screen graphic interface, MVES will offer both paid membership and “free” content, with the latter driven by AVOD that will allow users to stream movies for free with advertisements incorporated approximately every 15 minutes.

“EStreamTV is pleased to announce our partnership with The Movie Studio. The caliber of content they bring is exactly what we look to monetize with our advertiser partners,” said eSteamTV president Darren Cummings. “The content is also exactly what we look for to add to our Live TV, in-home Set Top Box platform. Our legacy advertiser partners could potentially bring such companies as Verizon, AOL, Bank of America, Toyota, and many more large advertisers. The synergy of both companies is incredible.”

MVES is a first-mover digital disrupter in the VOD space that has the potential to command significant market share given the recent increase in VOD consumption along with the closure of movie theaters and other forms of on-site entertainment due to COVID-19. Through its unique business model that fuses recent consumer trends favoring VOD, novel social media strategies, and a unique advertising model, MVES is in a favorable position to emerge as a unique brand within the rapidly shifting landscape of video-based entertainment.

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

From Our Blog

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

September 25, 2020

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, […]

Rotate your device 90° to view site.